These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 3625252)
1. Early stopping, interim analyses, and monitoring committees: what are the tradeoffs? Zelen M J Clin Oncol; 1987 Sep; 5(9):1314-5. PubMed ID: 3625252 [No Abstract] [Full Text] [Related]
2. Policies for study monitoring and interim reporting of results. Green SJ; Fleming TR; O'Fallon JR J Clin Oncol; 1987 Sep; 5(9):1477-84. PubMed ID: 3625262 [TBL] [Abstract][Full Text] [Related]
3. Stopping rules, interim analyses and data monitoring committees. Ashby D; Machin D Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354 [No Abstract] [Full Text] [Related]
4. Interim analyses, stopping rules and data monitoring in clinical trials in Europe. Buyse M Stat Med; 1993 Mar; 12(5-6):509-20. PubMed ID: 8493429 [TBL] [Abstract][Full Text] [Related]
5. Monitoring of clinical trials: issues and recommendations. Fleming TR; DeMets DL Control Clin Trials; 1993 Jun; 14(3):183-97. PubMed ID: 8339549 [TBL] [Abstract][Full Text] [Related]
6. Monitoring of clinical trials and interim analyses from a drug sponsor's point of view. Williams GW; Davis RL; Getson AJ; Gould AL; Hwang IK; Matthews H; Shih WJ; Snapinn SM; Walton-Bowen KL Stat Med; 1993 Mar; 12(5-6):481-92. PubMed ID: 8493426 [TBL] [Abstract][Full Text] [Related]
7. A survey of monitoring practices in cancer clinical trials. George SL Stat Med; 1993 Mar; 12(5-6):435-50. PubMed ID: 8493422 [TBL] [Abstract][Full Text] [Related]
8. Data monitoring committees: the moral case for maximum feasible independence. Walters L Stat Med; 1993 Mar; 12(5-6):575-80; discussion 581-2. PubMed ID: 8493433 [TBL] [Abstract][Full Text] [Related]
9. Data monitoring committees and capturing relevant information of high quality. Fleming TR Stat Med; 1993 Mar; 12(5-6):565-70; discussion 571-3. PubMed ID: 8493432 [TBL] [Abstract][Full Text] [Related]
10. Interview with Gary L. Yingling, J.D. Yingling GL Qual Manag Health Care; 1999; 7(3):45-7. PubMed ID: 10537462 [No Abstract] [Full Text] [Related]
11. Data monitoring committees for Southwest Oncology Group clinical trials. Green S; Crowley J Stat Med; 1993 Mar; 12(5-6):451-5. PubMed ID: 8493423 [TBL] [Abstract][Full Text] [Related]
13. Research infrastructure and IRB/FDA requirements. Cohen J Med Health R I; 2000 Dec; 83(12):382-5. PubMed ID: 11190124 [No Abstract] [Full Text] [Related]
14. The use of data monitoring committees in Canadian trial groups. Pater JL Stat Med; 1993 Mar; 12(5-6):505-8. PubMed ID: 8493428 [TBL] [Abstract][Full Text] [Related]
15. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules. Stegert M; Kasenda B; von Elm E; You JJ; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Briel M; J Clin Epidemiol; 2016 Jan; 69():152-60. PubMed ID: 26361993 [TBL] [Abstract][Full Text] [Related]
16. Safety and data monitoring committees for clinical trials. Conti CR Clin Cardiol; 1995 Aug; 18(8):432. PubMed ID: 7586759 [No Abstract] [Full Text] [Related]
18. Data monitoring committees, interim analysis and early termination in paediatric trials. Fernandes RM; van der Lee JH; Offringa M Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998 [TBL] [Abstract][Full Text] [Related]